Aquestive Therapeutics faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies

Reuters03-26

Aquestive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies

A securities lawsuit has been announced involving Aquestive over disclosures related to its Anaphylm new drug application (NDA).
The matter concerns statements and risk disclosures made during the period from June 16, 2025 through January 8, 2026.
On January 9, 2026, the company’s shares fell from $6.21 to $3.91 after the FDA flagged deficiencies in the Anaphylm NDA that precluded labeling discussions.
The lead plaintiff deadline stated in the announcement is May 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260900PR_NEWS_USPR_____NY19557) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622486867?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622486867","market":"us","top_or_hot":-1,"title":"Aquestive Therapeutics faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          A securities lawsuit has been announced involving Aquestive over disclosures related to its Anaphylm new drug application (NDA).\n        </li>\n<li>\n          The matter concerns statements and risk disclosures made during the period from June 16, 2025 through January 8, 2026.\n        </li>\n<li>\n          On January 9, 2026, the company’s shares fell from $6.21 to $3.91 after the FDA flagged deficiencies in the Anaphylm NDA that precluded labeling discussions.\n        </li>\n<li>\n          The lead plaintiff deadline stated in the announcement is May 4, 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AQST\">Aquestive Therapeutics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260900PR_NEWS_USPR_____NY19557) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aquestive Therapeutics faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAquestive Therapeutics faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          A securities lawsuit has been announced involving Aquestive over disclosures related to its Anaphylm new drug application (NDA).\n        </li>\n<li>\n          The matter concerns statements and risk disclosures made during the period from June 16, 2025 through January 8, 2026.\n        </li>\n<li>\n          On January 9, 2026, the company’s shares fell from $6.21 to $3.91 after the FDA flagged deficiencies in the Anaphylm NDA that precluded labeling discussions.\n        </li>\n<li>\n          The lead plaintiff deadline stated in the announcement is May 4, 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AQST\">Aquestive Therapeutics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260900PR_NEWS_USPR_____NY19557) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL74kft5:1","article_id":"2622486867","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622486867","pubTimestamp":1774530190,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A securities lawsuit has been announced involving Aquestive over disclosures related to its Anaphylm new drug application .The matter concerns statements and risk disclosures made during the period from June 16, 2025 through January 8, 2026.On January 9, 2026, the company’s shares fell from $6.21 to $3.91 after the FDA flagged deficiencies in the Anaphylm NDA that precluded labeling discussions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AQST":"Aquestive Therapeutics Inc."},"translate_title":"Aquestive Therapeutics面临证券诉讼；由于FDA引用Anaphylm NDA缺陷，股价从6.21美元跌至3.91美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":0.9},"content_text":"Aquestive Therapeutics faces securities lawsuit; shares fell from $6.21 to $3.91 on FDA-cited Anaphylm NDA deficiencies\n    \n\n\n          A securities lawsuit has been announced involving Aquestive over disclosures related to its Anaphylm new drug application (NDA).\n        \n\n          The matter concerns statements and risk disclosures made during the period from June 16, 2025 through January 8, 2026.\n        \n\n          On January 9, 2026, the company’s shares fell from $6.21 to $3.91 after the FDA flagged deficiencies in the Anaphylm NDA that precluded labeling discussions.\n        \n\n          The lead plaintiff deadline stated in the announcement is May 4, 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260900PR_NEWS_USPR_____NY19557) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622486867","isCrawlerRequest":true}